Invest. Engage. Save.

Rss

I Want My TB Drugs

Posted by: BIO Ventures for Global Health on 3/24/2010 | 0 Comments
Today’s TB drugs are over 40 years old, offering antiquated and inadequate tools to treat active TB, which is the primary cause of HIV-related death in Africa and the cause of more than 1.7 million deaths each year around the world. It’s a dismal situation. So what makes the outlook for this year’s World TB Day any different?

Coffee Break

Posted by: BIO Ventures for Global Health on 3/17/2010 | 2 Comments
Couldn't be in Seattle on March 17 for the Life Sciences Innovation Northwest Conference? No problem! You can view an ON DEMAND webcast about how the public and private sectors can work together to improve the health of poor people in developing countries, moderated by BIO Ventures for Global Health CEO Melinda Moree. Click the link above to find out how.
Categories: Meetings

Partnering 101

Posted by: BIO Ventures for Global Health on 3/8/2010 | 1 Comment
The BIO One-on-One Partnering™ system opened last Monday. The system is your secretary, your portal, and your who’s who list for the partnering activities that take place during the BIO Business Forum, May 4-6. In 2009 a record-setting 14,202 30-minute partnering meetings took place through the partnering system. And with over 1,000 organizations in the system, there can be a lot of information to sort through in order to make sure that you make the most of partnering opportunities during the event. Here are some tips to on how to make the most of your time.
Categories: Meetings Partnering

Partnering for Change

Posted by: BIO Ventures for Global Health on 3/2/2010 | 1 Comment
BVGH spoke with Mark Feinberg, VP of Medical Affairs and Policy, Merck Vaccines and Infectious Diseases, and a member of the 2010 Partnering for Global Health (PGH) Steering Committee about how to get the most out of partnering meetings. Mark's thoughts: "There is an incredible amount of partnering activity that happens at PGH, but only a subset of those meetings will ultimately result in the establishment of successful partnerships. To get the most out of these meetings, I would advise public sector organizations to spend time before the meeting identifying organizations with whom their interests are potentially best aligned and where potential partnerships might be possible."
Categories: Meetings
Page:

Blog Home
  
  

Recent Comments

by php flash chat on Speed Dating to Save Lives
"It was my first visit to your blog, but I admire time and effort you put into it! I have enjoyed reading many of your articles, looks like you are a professional writer! Well done! James, " Read more »

by simon on The Most Important Hire in Global Health
"I'd like to comment on the fact that the term "cost-effective" vaccines is not meaningful, since cost-effectiveness always depends on the Willigness to Pay of a given coutnry (which WHO recommends to be 1-3xGDP per capita). E.g. while in UK a medicines/vaccine that has incremental cost-effectiveness ratio of 43,000-130,000 USD/QALY will be considered "cost-effective", it will not be the case in India where the threshold is 1-3xGDP=1,000-3,000 USD/QALY. It means that the same vaccine would need to be 43x cheaper in India than in UK to be cost-effective. I believe that the future of developing countries will depend on their ability to develop vaccines locally and sell them at local prices. I am currently involved in a research project in India which aims at understanding the challenges of entrepreneurship and its role in affordable healthcare in the future. Best regards " Read more »

by Mark H on Trademark of Innovation
"Often the pharmaceutical companies are seen as evil because they do not do enough to help the poor by giving away medicines or licence rights. But we must consider two things: 1 they are commecial companies and have legal obligations towards their shareholders i.e. their prime concern is making money 2 these companies invest a vastly greater amount of money in R&D than the government. As a result their R&D occasionally finds cures inadvertently for other diseases - even if they are not actively trying to create the right medicine. So how do you create an incentive for the most effective creator of new innovative cures whose primary goal is to make money (like all companies)? Well the answer seems obvious - reward them with tax benefits that would help push them above their competitors. Whilst you could argue that this would prevent the government from reaping the benefits (tax) you could also say that the competition created would drive innovation and spending in the private sector which would improve the economy. A win win win situation - pharmaceuticals, government, developing countries!" Read more »

  

Tag Cloud